Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Cyclosporine on AT-527 PK in Healthy Males
NCT04849299Phase 1Completed
- Sponsor
- Atea Pharmaceuticals
- Start
- Apr 2021
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bemnifosbuvir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Atea Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration at Day 7 and Area Under the Curve at Day 7. Started Apr 2021; status: completed.
02
Drugs
bemnifosbuvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04849299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04849299.